FLT3 Y842H

CI-VAR-00004854Explore in graph →CIViC 3234

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia1
FLT3 Y842H	(predisposing)	Predisposing	C	N/A N/A	1	submitted	EID8929 Single strand polymorphism targeting FLT3 in addition to RUNX1, KIT, CEBPA, PTPN11, and NRAS was carried out to identify novel recurring gene mutations in an acute myeloid leukemia cohort comprised of… (full text at CIViC) PMID 15667533 · Smith et al., 2005 · Open in CIViC	civic
Malignant Neoplasm2
FLT3 ITD AND ( FLT3 D835V OR FLT3 D835Y OR FLT3 Y842C OR FLT3 F691L OR FLT3 Y842H )	Sorafenib	Predictive	D	Supports Resistance	3	submitted	EID12629 In an in-vitro study using an in vitro saturation mutagenesis assay, residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. These mutations… (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.